Sr. No. |
Age group (in
years) |
Total No. of cases |
Percentage |
1 |
20-29 |
4 |
1.3% |
2 |
30-39 |
69 |
22.8% |
3 |
40-49 |
154 |
50.8% |
4 |
50-59 |
50 |
16.5% |
5 |
60-69 |
25 |
8.3% |
6 |
≥70 |
1 |
0.3% |
7 |
|
303 |
100% |
Sr. No. |
Uterine lesions |
Total No. of
cases |
Percentage |
1 |
leiomyoma |
128 |
42.2% |
2 |
Adenomyosis |
25 |
8.3% |
3 |
Leiomyoma + Adenomyosis |
9 |
3% |
4 |
Adenomyoma |
4 |
1.3% |
5 |
Atrophy/cystic atrophy/ pressure atrophy |
88 |
29% |
6 |
Endometrial hyperplasia |
16 |
5.3% |
7 |
Endometrial polyp |
8 |
2.7% |
8 |
Endometrial carcinoma |
3 |
1 |
9 |
Low grade endometrial stromal sarcoma |
1 |
0.3% |
10 |
Placenta accrete (Chorionic villi) |
1 |
0.3% |
11 |
unremarkable |
20 |
6.6% |
12 |
Total |
303 |
100% |
Sr. No. |
Cervical lesions |
Total No. of
cases |
Percentage |
1 |
Chronic cervicitis |
85 |
28.1% |
2 |
Chronic papillary endocervicitis |
52 |
17.2% |
3 |
Squamous metaplasia |
30 |
9.9% |
4 |
Chronic cervicitis + Squamous metaplasia |
43 |
14.2% |
5 |
Chronic papillary endocervicitis + Squamous metaplasia |
8 |
2.6% |
6 |
Squamous cell carcinoma |
7 |
2.3% |
7 |
Endocervical polyp |
4 |
1.3% |
8 |
Mucinous endocervical adenocarcinoma |
1 |
0.3% |
9 |
Unremarkable |
73 |
24.1% |
10 |
Total |
303 |
100% |